SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), announced today that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company. This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.
IMIDomics Appointed Dr. Eric Perakslis to its Executive Team
IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases
IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board
SAN RAFAEL, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today that Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in the company. In conjunction with the investment, an Evotec representative will join the IMIDomics board of directors. No financial details were disclosed.